Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Kopran Limited is an India-based pharmaceutical manufacturer focused on active pharmaceutical ingredients (APIs), formulations, and contract manufacturing services. The company operates manufacturing facilities in Maharashtra with capabilities spanning antibiotics, cardiovascular drugs, and specialty APIs, serving both domestic Indian markets and regulated export markets including the US and Europe. Recent performance shows margin compression despite stable revenues, with significant capex deployment suggesting capacity expansion or regulatory compliance investments.
Kopran generates revenue through vertically integrated pharmaceutical manufacturing, producing both raw materials (APIs) and finished drug products. The company benefits from India's cost-competitive manufacturing base while targeting price-regulated markets where generic penetration drives volume growth. Pricing power is limited in generic APIs and formulations due to commoditization, but CDMO contracts can offer better margins through long-term supply agreements. The 35.7% gross margin reflects competitive API pricing and raw material costs, while the 26.1% operating margin indicates moderate fixed cost leverage from manufacturing facilities. Current negative free cash flow ($-0.1B) despite positive operating cash flow ($0.4B) is driven by elevated capex ($0.6B), likely for facility upgrades to meet US FDA or EU GMP standards.
US FDA or EU regulatory inspection outcomes and facility approval status - critical for export market access
API pricing trends for key molecules, particularly antibiotics and cardiovascular drugs where competition from Chinese manufacturers affects margins
CDMO contract wins with multinational pharmaceutical companies, which provide revenue visibility and margin stability
Capacity utilization rates at Maharashtra facilities following recent capex cycle
Indian rupee exchange rate movements affecting export realization and import raw material costs
Intensifying competition from Chinese API manufacturers with lower cost structures, particularly post-COVID as supply chain diversification pressures ease
Regulatory compliance costs escalating as US FDA and EU authorities increase inspection frequency and quality standards for Indian manufacturers
Generic drug pricing erosion in key markets due to government cost containment policies and increased competitive intensity from biosimilars
Larger Indian pharmaceutical companies (Sun Pharma, Dr. Reddy's, Cipla) have greater scale, R&D capabilities, and regulatory track records for complex generics
Multinational pharmaceutical companies increasingly insourcing API production or consolidating CDMO relationships with larger partners
Patent cliff opportunities diminishing as fewer blockbuster drugs lose exclusivity in coming years
Negative free cash flow ($-0.1B) creating potential liquidity pressure if capex cycle extends or revenue growth disappoints
Low ROE (3.3%) and ROA (2.1%) indicating inefficient capital deployment or margin compression requiring operational restructuring
Working capital intensity in pharmaceutical manufacturing requiring continuous funding for inventory and receivables
low - Pharmaceutical demand is relatively non-cyclical as healthcare spending remains stable across economic cycles. However, generic drug pricing faces secular pressure from government reimbursement policies and competitive intensity. The company's exposure to elective procedures or specialty drugs would be minimal given its generic focus.
Rising interest rates have moderate negative impact through higher working capital financing costs (pharmaceutical manufacturers typically carry 90-120 days of inventory) and potential valuation multiple compression for low-growth stocks. The 0.31 debt/equity ratio suggests manageable leverage, but the recent capex cycle may require additional borrowing. Lower rates in India (where the company likely borrows) would reduce financing costs and support valuation.
Moderate exposure to credit conditions through customer payment terms in export markets and distributor financing. Tighter credit conditions could extend receivables days or increase bad debt risk, particularly in emerging market exports. However, the 1.63 current ratio indicates adequate short-term liquidity.
value - The 1.0x price/sales and 1.3x price/book ratios suggest the stock trades at distressed valuations reflecting operational challenges. Investors are likely focused on turnaround potential from recent capex investments, regulatory approvals, or margin recovery. The -23.0% one-year return and negative free cash flow deter growth investors, while the lack of disclosed dividend yield limits income-focused buyers. Current holders are likely value investors betting on mean reversion or special situation investors anticipating catalysts from facility approvals or CDMO contract wins.
moderate-to-high - Small-cap pharmaceutical stocks in India exhibit elevated volatility due to regulatory event risk (FDA inspections), lumpy CDMO contract announcements, and currency fluctuations. The -15.7% six-month return indicates recent downward momentum, and the stock likely has beta above 1.2 relative to Indian equity indices. Volatility spikes typically occur around regulatory announcements or quarterly results showing margin surprises.
